Marc A. Cohen is a Co-founder of C4 Therapeutics and has served as Executive Chairman since the inception of the company in 2015. He also served as interim Chief Executive Officer of C4 Therapeutics from March to October 2020. Marc is also Co-Founder and Co-Chief Executive Officer of Bublup, Co-Founder and Co-Chief Executive Officer of Cobro Ventures and Chairman of the Board of Directors of Frequency Therapeutics (NASDAQ: FREQ). Previously, he was Chairman of the Board of Directors and Co-founder of Acetylon Pharmaceuticals (sold to Celgene) and Chairman of the Board of Directors and Chief Executive Officer of OPNET Technologies (sold to Riverbed Technology). Marc is also a Trustee of the Dana-Farber Cancer Institute where he is focusing on accelerating translational research and increasing the flow of new therapies to patients, as well as the co-founder of the Dana-Farber Innovations Research Fund, a venture philanthropy fund focused on early stage research.